Appendix 4G and Corporate Governance Statement

Apr 30, 2019
Posted in: Investor updates

Home » Appendix 4G and Corporate Governance Statement

Appendix 4G and Corporate Governance Statement

Apr 30, 2019
Posted in: Investor updates

Imagion Biosystems Appendix 4G and Corporate Governance Statement for the financial year ended 31 December 2018 is available. Download Appendix 4G.

Join Us at RSNA and SABCS: Advancing Molecular MRI for Cancer Detection

November 13, 2025

We are excited to announce that Imagion Biosystems (ASX: IBX) will be attending two premier medical conferences this fall: the Radiological Society of North

Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent

November 5, 2025

FDA Submission of IND for MagSense® HER2 Phase 2 Clinical Trial on Track Q4 2025 Key Highlights: Wayne State University Collaboration Program Delivers Positive and

Quarterly Activities Report – September 2025

October 21, 2025

Key Highlights: Positive Feedback from FDA Supports Company’s Plans to File an IND in Q4 2025 Wayne State University Collaboration in MRI adds to existing

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Appendix 4G and Corporate Governance Statement

Appendix 4G and Corporate Governance Statement

Related Articles

Join Us at RSNA and SABCS: Advancing Molecular MRI for Cancer Detection

Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent

Quarterly Activities Report – September 2025

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list